Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anixa Biosciences IncANIX · Entity 6698 | Director | September 23, 2026 | September 25, 2026 |
| PARKERVISION INCPRKR · Entity 7682 | Director | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anixa Biosciences Inc
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,046,003 |
Reported balance
After 2026-09-23 transaction · row 1
1 source rowRow 1 · 2026-09-23 · Purchase · Acquired 49,036 · Balance 1,046,003 |
PARKERVISION INC
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.24 · Expires 2031-01-22 | Direct | 370,000 |
Reported balance
After 2026-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-22 · Grant · Acquired 370,000 · Balance 370,000 F1: Option is awarded as compensation for 2026 Board service. Option vests in two, equal bi-annual increments on July 22, 2026 and January 22, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Option is awarded as compensation for 2026 Board service. Option vests in two, equal bi-annual increments on July 22, 2026 and January 22, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 6,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 7 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-07-17 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F5 · derivative.exercise_date: The option was originally granted on July 17, 2017 and vests and become exercisable in two equal installments on each September 30, 2017 and December 31, 2017. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 6 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2022-12-31 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F4 · derivative.exercise_date: The option was originally granted on March 28, 2013 and vested in in four (4) equal installments on each March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 5 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2022-12-31 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F4 · derivative.exercise_date: The option was originally granted on March 28, 2013 and vested in in four (4) equal installments on each March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 40,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 4 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2023-02-15 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted on February 15, 2013 and vested as follows: one third immediately and two thirds annually beginning on February 15, 2014. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 40,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 3 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-02-15 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted on February 15, 2013 and vested as follows: one third immediately and two thirds annually beginning on February 15, 2014. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 30,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F2 · derivative.exercise_date: The option was originally granted on September 19, 2012 and vested as follows: one third immediately and two thirds annually beginning on September 19, 2013. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 30,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F2 · derivative.exercise_date: The option was originally granted on September 19, 2012 and vested as follows: one third immediately and two thirds annually beginning on September 19, 2013. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 10:20 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 15,000 | $4.10 | $61,500.00 |
DisclosureSEC source: 0001513162-19-000207 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,544 Read SEC document |
| April 22, 2019 Filed Apr 22, 2019 15:15 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 50,000 | $4.09 | $204,500.00 |
DisclosureSEC source: 0001513162-19-000110 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891,544 Read SEC document |
| October 25, 2018 Filed Oct 26, 2018 09:50 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 2,000 | $4.05 | $8,100.00 |
DisclosureSEC source: 0001513162-18-000269 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 841,544 Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 20:13 UTC | PARKERVISION INC PRKR · Entity 7682 | GrantOption (Right to buy) · Derivative | 125,000 | $0.60 Strike: $0.60 | $75,000.00 |
DisclosureSEC source: 0001562762-18-000316 · certent-form4.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common stock · 125,000 shares Expires 2025-09-24 F1 · derivative.exercise_date: Share options vest in 4 equal quarterly installments beginning December 24, 2018. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 11:18 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.98 | $19,900.00 |
DisclosureSEC source: 0001513162-18-000234 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,544 Read SEC document |
| July 26, 2018 Filed Jul 27, 2018 16:53 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 300,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001513162-18-000171 · primary_doc.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-07-26 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on a quarterly basis over three years beginning on October 31, 2018. Read SEC document |
| October 19, 2017 Filed Oct 23, 2017 17:54 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Exercise / conversionEmployee Stock Option · Derivative | 2,400 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001513162-17-000284 · primary_doc.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2017-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Right-To-Buy, pursuant to the ITUS Corporation 2010 Share Incentive Plan. Read SEC document |
| October 19, 2017 Filed Oct 23, 2017 17:54 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Exercise / conversionCommon Stock | 2,400 | $0.67 | $1,608.00 |
DisclosureSEC source: 0001513162-17-000284 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 20:18 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001513162-17-000265 · primary_doc.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-09-22 F2 · security: Right-To-Buy, pursuant to the Plan. F3 · derivative.exercise_date: The options vest and become exercisable in four (4) equal installments on each of December 31, 2017, March 31, 2018, June 30, 2018 and September 30, 2018. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 20:18 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001513162-17-000265 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832,144 F1 · security: Stock Award granted under the ITUS Corporation 2010 Share Incentive Plan (the "Plan"). F1 · price: Stock Award granted under the ITUS Corporation 2010 Share Incentive Plan (the "Plan"). Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 18 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2026-01-14 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F10 · derivative.exercise_date: The option was originally granted on February 18, 2016 and vested in four (4) equal installments on each of March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $2.92 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 17 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2026-01-14 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F10 · derivative.exercise_date: The option was originally granted on February 18, 2016 and vested in four (4) equal installments on each of March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 16 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2025-01-02 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F9 · derivative.exercise_date: The option was originally granted on January 2, 2015 and vested in four (4) equal installments on each of March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 15 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2025-01-02 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F9 · derivative.exercise_date: The option was originally granted on January 2, 2015 and vested in four (4) equal installments on each of March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 14 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2023-12-31 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F8 · derivative.exercise_date: The option was originally granted on January 2, 2014 and vested in four (4) equal installments on each of March 31, 2014, June 30, 2014, September 30, 2014 and December 31, 2014. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 13 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2023-12-31 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F8 · derivative.exercise_date: The option was originally granted on January 2, 2014 and vested in four (4) equal installments on each of March 31, 2014, June 30, 2014, September 30, 2014 and December 31, 2014. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 120,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 12 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2023-11-08 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F7 · derivative.exercise_date: The option was originally granted on November 8, 2013 and vested in 36 consecutive monthly installments beginning on December 31, 2013. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 120,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 11 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2023-11-08 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F7 · derivative.exercise_date: The option was originally granted on November 8, 2013 and vested in 36 consecutive monthly installments beginning on December 31, 2013. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 2,400 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 10 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 2,400 shares Expires 2017-11-30 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F6 · derivative.exercise_date: The option was originally granted on November 30, 2012 and vested immediately. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 2,400 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 9 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2017-11-30 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F6 · derivative.exercise_date: The option was originally granted on November 30, 2012 and vested immediately. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 6,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 8 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-07-17 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F5 · derivative.exercise_date: The option was originally granted on July 17, 2017 and vests and become exercisable in two equal installments on each September 30, 2017 and December 31, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 6,000 | Not disclosed Strike: $0.82 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 7 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-07-17 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F5 · derivative.exercise_date: The option was originally granted on July 17, 2017 and vests and become exercisable in two equal installments on each September 30, 2017 and December 31, 2017. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 6 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2022-12-31 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F4 · derivative.exercise_date: The option was originally granted on March 28 2013 and vested in in four (4) equal installments on each March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 5 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2022-12-31 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F4 · derivative.exercise_date: The option was originally granted on March 28 2013 and vested in in four (4) equal installments on each March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 40,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 4 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2023-02-15 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted on February 15, 2013 and vested as follows: one third immediately and two thirds annually beginning on February 15, 2014. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 40,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 3 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-02-15 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F3 · derivative.exercise_date: The option was originally granted on February 15, 2013 and vested as follows: one third immediately and two thirds annually beginning on February 15, 2014. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Option · Derivative | 30,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F2 · derivative.exercise_date: The option was originally granted on September 19, 2012 and vested as follows: one third immediately and two thirds annually beginning on September 19, 2013. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 19:17 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 30,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-17-000257 · primary_doc.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-09-19 F1 · kind: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F2 · derivative.exercise_date: The option was originally granted on September 19, 2012 and vested as follows: one third immediately and two thirds annually beginning on September 19, 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.